Xcopri 12.5 mg (Cenobamate KIT) 12.5 MG

XCOPRI 12.5 MG is a medication used to manage certain types of seizures. This oral kit contains cenobamate, a compound known for its anticonvulsant properties. Ideal for those seeking seizure management solutions.

Strength

12.5 MG

Manufacturer / TM Owner

ENDO OPERATIONS LTD.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

XCOPRI 12.5 MG is primarily used as an adjunctive therapy for partial-onset seizures in adults. It works by stabilizing electrical activity in the brain, which can help reduce the frequency of seizures. People often ask, 'What is XCOPRI used for?' and the answer lies in its ability to provide additional control for those who have not responded adequately to other treatments.

Side Effects

Common effects of XCOPRI 12.5 MG may include dizziness, fatigue, and somnolence. Some users also report experiencing headaches or nausea. These effects can vary from person to person and may diminish over time as the body adjusts to the medication.

Precautions & Warnings

XCOPRI 12.5 MG should be handled with care. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Avoid abrupt discontinuation without medical advice, as this can lead to withdrawal symptoms or increased seizure frequency.

Avoid Interactions

XCOPRI 12.5 MG may interact with other medications, including those metabolized by the liver's CYP enzymes. Alcohol and certain anticonvulsants can also affect its efficacy. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

XCOPRI 12.5 MG is used as an adjunctive therapy for partial-onset seizures in adults.

XCOPRI 12.5 MG is taken orally, typically as directed by a healthcare professional.

Common side effects may include dizziness, fatigue, somnolence, headaches, and nausea.

XCOPRI 12.5 MG may interact with other medications, so it's important to consult a healthcare provider before combining it with other treatments.

Follow the prescribed dosage and administration instructions, and avoid abrupt discontinuation without medical advice.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.